Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3064408 | Journal of Neuroimmunology | 2011 | 9 Pages |
Abstract
Glatiramer acetate (GA, Copaxone®, co-polymer 1) is an immunomodulatory therapy approved in 1996 by the United States Food and Drug Administration for treatment of relapsing–remitting multiple sclerosis. GA has a good safety profile, moderate efficacy, and a unique mode of action. Recent evidence in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), suggests that GA effects on NK cells and B cells may contribute to therapeutic efficacy. We review the mechanism of action of GA, with particular focus on recent data suggesting a role for regulatory B cells.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mrinalini Kala, Augusto Miravalle, Timothy Vollmer,